CRISPR therapies march into clinic, but genotoxicity concerns linger
By Cormac Sheridan,
Nature
| 07. 15. 2021
A recent study has identified another potential hazard for developers of genome editing therapies based on CRISPR–Cas9. The double-strand DNA breaks introduced during CRISPR editing could result in chromothripsis, an extremely damaging form of genomic rearrangement that results from the shattering of individual chromosomes and the subsequent rejoining of the pieces in a haphazard order. Although most cells do not remain viable after undergoing such a dramatic alteration, those that do could, in theory, express oncogenic fusion proteins or give rise to dysregulated expression of particular genes that could cause problems.
So far, none of the companies leading the clinical development of CRISPR-based therapies appears to have considered the issue; its clinical implications, if any, remain unclear. However, the study, led by Mitchell Weiss of St. Jude Children’s Research Hospital and David Pellman of the Dana–Farber Cancer Institute and Harvard Medical School, adds another layer of complexity to gene-editing’s already relatively complicated mechanism of action. “Most importantly, it’s an on-target effect. You cannot make this go away by making the cutting more specific,” says Pellman.
The study is the...
Related Articles
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Simar Bajaj, The New York Times | 11.27.2025
A common cold was enough to kill Cora Oakley.
Born in Morristown, N.J., with virtually no immune system, Cora was diagnosed with severe combined immunodeficiency, a rare genetic condition that leaves the body without key white blood cells.
It’s better...
